Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas, 78712, USA.
DisperSol Technologies, LLC, 111 Cooperative Way, Georgetown, Texas, 78626, USA.
AAPS PharmSciTech. 2018 Jul;19(5):1998-2008. doi: 10.1208/s12249-017-0903-1. Epub 2017 Nov 30.
The formulation factors relevant to developing immediate and controlled release dosage forms containing poorly soluble drugs dispersed in amorphous systems are poorly understood. While the utility of amorphous solid dispersions is becoming apparent in the pharmaceutical marketplace, literature reports tend to concentrate on the development of solid dispersion particulates, which then must be formulated into a tablet. Amorphous solid dispersions of itraconazole in high molecular weight hydroxypropyl methylcellulose were prepared by KinetiSol® Dispersing and tablets were formulated to immediately disintegrate or control the release of itraconazole. Formulated tablets were evaluated by two non-sink dissolution methodologies and the dosage form properties that controlled the gelling tendency of the dispersion carrier, hydroxypropyl methylcellulose, were investigated. Selected formulations were evaluated in an exploratory beagle dog pharmacokinetic study; the results of which indicate potential for a prolonged absorption phase relative to the commercially extruded control.
对于开发含有分散在无定形系统中的难溶性药物的即刻和控制释放剂型,相关的制剂因素了解甚少。虽然无定形固体分散体在药物市场中的应用越来越明显,但文献报道往往侧重于固体分散体颗粒的开发,然后必须将其制成片剂。通过 KinetiSol®Dispersing 制备伊曲康唑的高分子量羟丙基甲基纤维素无定形固体分散体,并将其制成即刻崩解或控制伊曲康唑释放的片剂。通过两种非溶出度测定方法评估了所制备的片剂,并研究了控制分散载体羟丙基甲基纤维素胶凝倾向的剂型特性。对选定的配方进行了探索性比格犬药代动力学研究;结果表明,相对于商业挤出的对照品,可能存在延长的吸收相。